Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), announced a collaboration with Tempus AI Inc. (NASDAQ: TEM) to integrate blood-based Alzheimer's biomarker testing into clinical workflows. The partnership will enable neurologists to order the LucentAD Complete multi-biomarker blood test through Tempus' clinical ordering platform.

Under the agreement, Tempus AI will develop a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing. The program aims to identify patients eligible for biomarker testing through clinical guidelines and provide neurologists with streamlined ordering capabilities through existing electronic health record integrations.

According to the announcement, more than 7 million Americans currently live with Alzheimer's disease, though only a small portion are evaluated for eligibility for approved treatments. The collaboration seeks to address this gap by embedding clinical guideline-directed identification and blood-based biomarker testing options into neurologists' decision-making workflows.

"This collaboration represents an important step toward ensuring blood-based Alzheimer's biomarker testing becomes part of routine clinical practice," said Everett Cunningham, CEO of Quanterix. "By working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, we are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies."

Tempus Next is described as an AI-enabled care pathway intelligence platform that identifies care gaps and provides actionable insights consistent with clinical guidelines at the point of care. Lucent Diagnostics was created in 2023 as a commercial brand of Quanterix to deliver tools for earlier detection of cognitive disease using Simoa technology.